Related Experiment Video

Updated: Oct 14, 2026

Construction of Vapor Chambers Used to Expose Mice to Alcohol During the Equivalent of all Three Trimesters of Human Development
15:27

Construction of Vapor Chambers Used to Expose Mice to Alcohol During the Equivalent of all Three Trimesters of Human Development

Published on: July 13, 2014

Biochemical and developmental features of experimental phenylketonuria induced by L-ethionine in suckling rats

J Gehrmann1, K Schott, V Neuhoff

  • 1Max-Planck Institut für Experimentelle Medizin, Forschungsstelle Neurochemie, Göttingen, Federal Republic of Germany.

Biochemical Medicine and Metabolic Biology
|June 1, 1989
PubMed

Insights

L-ethionine administration in suckling rats induced hyperphenylalaninemia and phenylketonuria, impairing brain development. However, severe side effects limit its use as a phenylketonuria model.

Area of Science:

  • Biochemistry
  • Neuroscience
  • Toxicology

Background:

  • Phenylketonuria (PKU) is a genetic disorder characterized by impaired phenylalanine metabolism.
  • Animal models are crucial for understanding PKU pathogenesis and testing interventions.
  • L-ethionine is an amino acid analog that can induce metabolic disturbances.

Purpose of the Study:

  • To investigate the effects of L-ethionine administration on amino acid metabolism and brain development in suckling rats.
  • To evaluate L-ethionine as a potential animal model for phenylketonuria.

Main Methods:

  • Suckling rats were subcutaneously injected with L-ethionine.
  • Phenylalanine hydroxylase activity, amino acid concentrations, ATP content, and cathepsin D activity were measured.
  • Body weight and mortality were monitored.

Main Results:

  • L-ethionine induced hyperphenylalaninemia and phenylketonuria by inhibiting phenylalanine hydroxylase.
  • Female rats showed greater sensitivity to L-ethionine.
  • Significant alterations in serum and brain amino acid profiles, decreased ATP, and increased cathepsin D activity were observed.
  • Hyperphenylalaninemia and amino acid imbalances impaired brain development.
  • Side effects included high mortality, weight loss, and delayed development.

Conclusions:

  • L-ethionine effectively models hyperphenylalaninemia and phenylketonuria in suckling rats.
  • The observed side effects, including developmental delays and mortality, restrict its utility as a precise model for classic phenylketonuria.
  • Further research is needed to refine ethionine-induced models or explore alternative approaches for PKU research.

More Related Videos

Non-Invasive Model of Neuropathogenic Escherichia coli Infection in the Neonatal Rat08:27

Non-Invasive Model of Neuropathogenic Escherichia coli Infection in the Neonatal Rat

Published on: October 29, 2014

Modeling Encephalopathy of Prematurity Using Prenatal Hypoxia-ischemia with Intra-amniotic Lipopolysaccharide in Rats07:36

Modeling Encephalopathy of Prematurity Using Prenatal Hypoxia-ischemia with Intra-amniotic Lipopolysaccharide in Rats

Published on: November 20, 2015

Related Concept Videos

Overview of Protein Metabolism01:21

Overview of Protein Metabolism

Proteins are broken down into amino acids during digestion. Unlike fats and carbohydrates, which are stored for later use, proteins are not. Instead, amino acids are either used to produce ATP through oxidation or contribute to the creation of new proteins for the growth and repair of the body. Any surplus amino acids from the diet are converted into glucose or triglycerides rather than excreted.
Amino acids play various roles in the body once they are absorbed into cells. They are restructured...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...